Elisa Perry
Overview
Explore the profile of Elisa Perry including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
195
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Osman M, Iravani A, Mitchell C, Hicks R, Perry E, Hofman M
J Nucl Med
. 2024 Aug;
65(9):1383-1386.
PMID: 39089815
We evaluated the incidence and potential etiology of tracheobronchial uptake in patients being evaluated by F-DCFPyL PET/CT for prostate cancer (PCa). The study included a consecutive 100 PCa patients referred...
2.
Wong L, Sutherland T, Perry E, Tran V, Spelman T, Corcoran N, et al.
Eur Urol Oncol
. 2024 Jan;
7(5):1015-1023.
PMID: 38281891
Background And Objective: Multiparametric magnetic resonance imaging (mpMRI) of the prostate is used for prostate cancer diagnosis. However, mpMRI has lower sensitivity for small tumours. Prostate-specific membrane antigen positron emission...
3.
Emmett L, Papa N, Counter W, Calais J, Barbato F, Burger I, et al.
J Nucl Med
. 2023 Dec;
65(1):94-99.
PMID: 38050155
The PRIMARY score is a 5-category scale developed to identify clinically significant intraprostate malignancy (csPCa) on Ga-prostate-specific membrane antigen (PSMA)-11 PET/CT (Ga-PSMA PET) using a combination of anatomic site, pattern,...
4.
Wong L, Koschel S, Whish-Wilson T, Farag M, Bolton D, Zargar H, et al.
World J Urol
. 2023 Jan;
41(2):463-469.
PMID: 36602577
Background: To determine the utility of diagnostic 18F-DCPyL PSMA-PET/CT to aid management of men with highly suspicious multiparametric MRI prostate (PIRAD 4-5 lesions) and discrepant negative prostate biopsy. Methods: A...
5.
Tran V, Hong A, Sutherland T, Taubman K, Lee S, Lenaghan D, et al.
BMJ Open
. 2022 Sep;
12(9):e061815.
PMID: 36123093
Introduction: Prostate-specific membrane antigen positron emission tomography (PSMA-PET) has emerged as valuable imaging to assessing metastatic disease in prostate malignancy. However, there has been limited studies exploring the utility PSMA-PET...
6.
Perry E, Talwar A, Taubman K, Ng M, Wong L, Sutherland T
BJU Int
. 2022 Jun;
130 Suppl 1:28-36.
PMID: 35768883
Objectives: To assess the correlation of pathological radical prostatectomy (RP) specimen features and prostate-specific antigen (PSA) characteristics to imaging findings on subsequent F-DCFPyL positron emission tomography/computed tomography (PET/CT) in patients...
7.
Perry E, Talwar A, Sharma S, OConnor D, Wong L, Taubman K, et al.
Eur J Nucl Med Mol Imaging
. 2022 Mar;
49(9):3277-3288.
PMID: 35254481
Purpose: With increasing use of PSMA PET/CT in the staging and restaging of prostate cancer (PCa), the identification of non-prostate cancer tumours (NPCaT) has become an increasing clinical dilemma. Atypical...
8.
Parathithasan N, Perry E, Taubman K, Hegarty J, Talwar A, Wong L, et al.
J Med Imaging Radiat Oncol
. 2022 Feb;
66(7):927-935.
PMID: 35170858
Introduction: Clinical and biochemical assessment and biopsies can miss clinically significant prostate cancers (csPCa) in up to 20% of patients and diagnose clinically insignificant tumours leading to overtreatment. This retrospective...
9.
Perry E, Talwar A, Taubman K, Ng M, Wong L, Booth R, et al.
Eur J Nucl Med Mol Imaging
. 2021 Jan;
48(6):2038-2046.
PMID: 33399941
Purpose: The primary aim of this retrospective multicenter analysis was to assess the performance of PSMA PET/CT using [F]DCFPyL in the detection and localization of recurrent prostate cancer post radical...
10.
Perry E, Moore H, Reeve J
J Med Imaging Radiat Oncol
. 2019 Feb;
63(2):203-211.
PMID: 30785667
Introduction: There is no consensus as to the most optimal bowel preparation regime for Computed Tomographic Colonography (CTC). Concerns regarding laxative bowel preparation (LBP) include tolerability, adverse effects and complexity...